Advertisement
Research Article Free access | 10.1172/JCI117704
Department of Medicine, UCLA School of Medicine 90024.
Find articles by Harwig, S. in: JCI | PubMed | Google Scholar
Department of Medicine, UCLA School of Medicine 90024.
Find articles by Tan, L. in: JCI | PubMed | Google Scholar
Department of Medicine, UCLA School of Medicine 90024.
Find articles by Qu, X. in: JCI | PubMed | Google Scholar
Department of Medicine, UCLA School of Medicine 90024.
Find articles by Cho, Y. in: JCI | PubMed | Google Scholar
Department of Medicine, UCLA School of Medicine 90024.
Find articles by Eisenhauer, P. in: JCI | PubMed | Google Scholar
Department of Medicine, UCLA School of Medicine 90024.
Find articles by Lehrer, R. in: JCI | PubMed | Google Scholar
Published February 1, 1995 - More info
We purified a molecule from the murine small intestine that killed both Escherichia coli and Listeria monocytogenes, and identified it as intestinal phospholipase A2 (iPLA2) by NH2-terminal sequencing and enzymatic measurements. The ability of iPLA2 to kill. L. monocytogenes was greatly enhanced by 5 mM calcium, inhibited by EGTA and abolished after reduction and alkylation, suggesting that enzymatic activity was required for iPLA2-mediated bactericidal activity. A mouse-avirulent phoP mutant, S. typhimurium 7953S, was 3.5-fold more susceptible to iPLA2 than its isogenic virulent parent, S. typhimurium 14028S (estimated minimal bactericidal concentrations 12.7 +/- 0.5 micrograms/ml vs. 43.9 +/- 4.5 micrograms/ml P < 0.001). Overall, these findings identify iPLA2 as part of the antimicrobial arsenal that equips Paneth cells to protect the small intestinal crypts from microbial invasion. Because iPLA2 is identical to Type 2 phospholipase A2 molecules found in other sites, including spleen, platelets and inflammatory exudate cells, this enzyme may also contribute to antibacterial defenses elsewhere in the body.
Images.